Cipla's US Recovery and Biosimilar Pipeline Boost Growth Outlook
Cipla's September-quarter earnings were impacted by a high base in its US business but showed sequential growth driven by strong performance in India and branded prescription therapies. Recent approvals of respiratory products and an expanding biosimilar pipeline support Cipla's positive growth outlook. Despite declining operating margins, the company expects improvements through new product launches and is exploring inorganic opportunities to strengthen its specialty portfolio.
ET Markets·




